Topotecan in the treatment of brain metastases. A phase II study of GOIM (Gruppo Oncologico dell'Italia Meridionale)

Anticancer Research

Volumn 26, Issue 3 B, 2006, Pages 2259-2263

  Lorusso, Vito ^a   Galetta, Domenico ^a   Giotta, Francesco ^a   Rinaldi, Antonio ^b   Romito, Sante ^c   Brunetti, Cosimo ^d   Silvestris, Nicola ^e   Colucci, Giuseppe ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b Castellaneta Hospital   (Italy)

^c Cardarelli Hospital   (Italy)

^d Manduria Hospital   (Italy)

^e Medical Oncology   (Italy)

Author keywords

Brain metastases; Topotecan

Indexed keywords

TAXANE DERIVATIVE; TOPOTECAN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; BRAIN METASTASIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEMALE; HUMAN; LUNG SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SCORING SYSTEM; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CARCINOMA, SMALL CELL; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; OVARIAN NEOPLASMS; TOPOTECAN;

EID: 33745524526     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Patchell R: Brain metastases. Handbook Neurol 25: 135-149, 1997.
2. Posner JB: Management of brain metatases. Rev Neurol 148: 477-487, 1992.
3. Johnson JD and Young B: Demographics of brain metastasis. Neurosurg Clin North Am 7: 337-344, 1996.
4. Loeffler JS, Patchell RA and Sawaya R: Metastatic brain cancer. In: Cancer: Principles and Practice of Oncology. Devita VT, Hellman S and Rosemberg SA (eds.). Philadelphia, JP Lippincott, pp. 2523, pp. 77-110, 1997.
5. Posner JB: Neurologic Complications of Cancer, Philadelphia, FA Davis, pp. 77-110, 1995.
6. Paterson AH, Agarwal M, Less A et al: Brain metastases in breast cancer patients receiving adjuvant chemotherapy. Cancer 49: 651-654, 1982.
7. Komaki R, Cox ID and Stark R: Frequency of brain metastasis in adenocarcinoma and large cell carcinoma of the lung: correlation with survival. Int J Radiat Oncol Biol Phys 9: 1467-1470, 1983.
8. Zimm S, Wampler G, Stablein D et al: Intracerebral metastases in solid-tumor patients: natural history and results of treatment. Cancer 41: 384-394, 1981.
9. Fujita A, Fukoka S, Takabatake H et al: Combination chemotherapy of cisplatin, ifosfamide, and irinotecan, with rhG-CSF support in patients with brain metastases from non-small cell lung cancer. Oncology 59: 291-295, 2000.
10. Postmus PE, Haaxma-Reiche H, Smit EF et al: Treatment of brain metastases of small cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy. A phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 18: 3400-3408, 2000.
11. von Pawel J, Gatzmeier U, Pujol JL et al: Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small cell lung cancer. J Clin Oncol 19: 1743-1749, 2001.
12. von Pawel J, Schiller JH, Shepherd FA et al: Topotecan versus cyclophosphamide, doxorubicin and vincristine for the treatment of recurrent small cell lung cancer. J Clin Oncol 17: 658-667, 1999.
13. Depierre A, von Pawel J, Hans K et al: Evaluation of topotecan (Hycamtin) in relapsed small cell lung cancer (SLCLC). A multicentre phase II study. Lung Cancer 18(suppl 1): 35, 1997.
14. Eckardt J, Gralla R, Palmer MC et al: Topotecan (T) as second-line therapy in patients (pts) with small cell lung cancer (SCLC): a phase II study. Ann Oncol 7(suppl 5): 107, 1996.
15. Sung C, Blaney SM, Cole DE et al: A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid. Cancer Res 54: 5118-5122, 1994.
16. Blaney SM, Cole DE, Balis FM et al: Plasma and cerebrospinal fluid pharmacokinetics study of topotecan in nonhuman primates. Cancer Res 55: 725-727, 1993.
17. Baker SD, Heideman RL, Crom WR et al: Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumours. Cancer Chemother Pharmacol 37: 195-202, 1996.
18. Zamboni WC, Luftner DI, Egorin MJ et al: The effect of increasing topotecan infusion from 30 minutes to 4 hours on the duration of exposure in cerebrospinal fluid. Ann Oncol 12: 119-122, 2001.
19. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clinical Trials 10(1): 1-10, 1989.
20. Sawaya R and Bindal RJ: Metastatic brain tumors. In: Brain Tumors, Kaye AH and Laws ER (eds.). New York Churcill Livingstone, pp. 923-926, 1997.
21. Lagerwaard FJ, Levendag PC, Nowak PJ et al: Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys 43; 795-803, 1999.
22. Lesser GJ: Chemotherapy of cerebral metastases from solid tumors. Neurosurg Clin North Am 7: 527-536, 1996.
23. Franciosi V, Cocconi G, Michiara M et al: Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, non small cell carcinoma or malignant melanoma: a prospective study. Cancer 85: 1599-1605, 1999.
24. Oberoff C, Kierback DJ, Wurstlein R et al: Topotecan chemotherapy in patients with breast cancer and brain metastases: results of a pilot study. Onkologie 24: 256-260, 2001.
25. Manegold C, Pawel JV, Scheithouer W et al: Response of SCLC brain metastases on topotecan therapy. Ann Oncol 7(supp5): 106-107, 1996.
26. Ardizzoni A, Hansen H, Dombrenowsky P et al: Topotecan, a new active drug in the second line treatment of small cell lung cancer: a phase II study in patients with refractory and sensitive disease. J Clin Oncol 15: 2090-2096, 1997.
27. Shutte W, Manegold C, von Pawel JV et al: Topotecan - a new treatment option in the therapy of brain metastases of lung cancer. Front Radiat Ther Oncol 33: 354-363, 1999.
28. Korfel A, Oehm C, von Pawel J et al: Response to topotecan of symptomatic brain metastases of small cell lung cancer also after whole brain irradiation: a multicentre phase II study. Eur J Cancer 38: 1724-1729, 2002.